Literature DB >> 19409534

Increased vulnerability to depressive-like behavior of mice with decreased expression of VGLUT1.

Alvaro L Garcia-Garcia1, Natalia Elizalde, Denis Matrov, Jaanus Harro, Sonja M Wojcik, Elisabet Venzala, Maria J Ramírez, Joaquin Del Rio, Rosa M Tordera.   

Abstract

BACKGROUND: Many studies link depression to an increase in the excitatory-inhibitory ratio in the forebrain. Presynaptic alterations in a shared pathway of the glutamate/gamma-aminobutyric acid (GABA) cycle may account for this imbalance. Evidence suggests that decreased vesicular glutamate transporter 1 (VGLUT1) levels in the forebrain affect the glutamate/GABA cycle and induce helpless behavior. We studied decreased VGLUT1 as a potential factor enhancing a depressive-like phenotype in an animal model.
METHODS: Glutamate and GABA synthesis as well as oxidative metabolism were studied in heterozygous mice for the VGLUT1+/- and wildtype. The regulation of neurotransmitter levels, proteins involved in the glutamate/GABA cycle, and behavior by both genotype and chronic mild stress (CMS) were studied. Finally, the effect of chronic imipramine on VGLUT1 control and CMS mice was studied.
RESULTS: VGLUT1+/- mice showed increased neuronal synthesis of glutamate; decreased cortical and hippocampal GABA, VGLUT1, and excitatory amino acid transporter 1 (EAAT1) as well as helplessness and anhedonia. CMS induced an increase of glutamate and a decrease of GABA, the vesicular GABA transporter (VGAT), and glutamic acid decarboxylase 65 (GAD65) in both areas and led to upregulation of EAAT1 in the hippocampus. Moreover, CMS induced anhedonia, helplessness, anxiety, and impaired recognition memory. VGLUT1+/- CMS mice showed a combined phenotype (genotype plus stress) and specific alterations, such as an upregulation of VGLUT2 and hyperlocomotion. Moreover, an increased vulnerability to anhedonia and helplessness reversible by chronic imipramine was shown.
CONCLUSIONS: These studies highlight a crucial role for decreased VGLUT1 in the forebrain as a biological mediator of increased vulnerability to chronic mild stress.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19409534     DOI: 10.1016/j.biopsych.2009.02.027

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  44 in total

Review 1.  Contribution of Vesicular Glutamate Transporters to Stress Response and Related Psychopathologies: Studies in VGluT3 Knockout Mice.

Authors:  Hanga Réka Horváth; Csilla Lea Fazekas; Diána Balázsfi; Subodh Kumar Jain; József Haller; Dóra Zelena
Journal:  Cell Mol Neurobiol       Date:  2017-08-03       Impact factor: 5.046

2.  Presynaptic glutamatergic dysfunction in bipolar disorder.

Authors:  Guang Chen; Ioline D Henter; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2010-06-01       Impact factor: 13.382

Review 3.  Animal models of stress vulnerability and resilience in translational research.

Authors:  Sebastian H Scharf; Mathias V Schmidt
Journal:  Curr Psychiatry Rep       Date:  2012-04       Impact factor: 5.285

Review 4.  Neurobiology of chronic mild stress: parallels to major depression.

Authors:  Matthew N Hill; Kim G C Hellemans; Pamela Verma; Boris B Gorzalka; Joanne Weinberg
Journal:  Neurosci Biobehav Rev       Date:  2012-07-07       Impact factor: 8.989

Review 5.  Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.

Authors:  Judith Pratt; Catherine Winchester; Neil Dawson; Brian Morris
Journal:  Nat Rev Drug Discov       Date:  2012-06-22       Impact factor: 84.694

6.  Candidate hippocampal biomarkers of susceptibility and resilience to stress in a rat model of depression.

Authors:  Kim Henningsen; Johan Palmfeldt; Sofie Christiansen; Isabel Baiges; Steffen Bak; Ole Nørregaard Jensen; Niels Gregersen; Ove Wiborg
Journal:  Mol Cell Proteomics       Date:  2012-02-06       Impact factor: 5.911

7.  Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia.

Authors:  Colm M P O'Tuathaigh; Brian P Kirby; Paula M Moran; John L Waddington
Journal:  Schizophr Bull       Date:  2009-11-24       Impact factor: 9.306

Review 8.  The role of the central noradrenergic system in behavioral inhibition.

Authors:  Eric A Stone; Yan Lin; Yasmeen Sarfraz; David Quartermain
Journal:  Brain Res Rev       Date:  2011-03-05

9.  Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?

Authors:  Márcia Calheiros Chaves Silva; Caren Nádia Soares de Sousa; Luis Rafael Leite Sampaio; Naiara Coelho Ximenes; Paulo Victor Pontes Araújo; Jéssica Calheiros da Silva; Suzyana Lima de Oliveira; Francisca Cléa Florenço Sousa; Danielle Silveira Macêdo; Silvânia Maria Mendes Vasconcelos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-16       Impact factor: 3.000

Review 10.  Treatment-resistant depression: are animal models of depression fit for purpose?

Authors:  Paul Willner; Catherine Belzung
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.